Nurix Therapeutics announced a targeted workforce reduction while initiating the DAYBreak pivotal Phase 2 trial of its oral BTK degrader bexobrutideg in relapsed or refractory chronic lymphocytic leukemia. The company framed the cuts as a strategic realignment to prioritize programs with the highest potential to advance toward registration and commercialization. Nurix launched the DAYBreak study on Oct. 22 and plans a confirmatory Phase 3 in the first half of 2026. Bexobrutideg is designed to degrade Bruton's tyrosine kinase rather than merely inhibit it, targeting patients whose disease has progressed after existing BTK inhibitors. “The initiation of the DAYBreak study marks Nurix’s transition to a pivotal‑stage company and a major milestone for bexobrutideg,” CEO Arthur Sands said in the company release, while stressing that no programs were being paused as a result of the reorganization.